<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-62893</identifier>
<setSpec>0001-7310</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Efficacy of short and long term efalizumab</dc:title>
<dc:description xml:lang="en">T cells play an important role in the immune system and in the inflammatory response that determines the development and maintenance of psoriasis plaques. Better understanding of the pathophysiology of this disease has led to the development of specific biological treatments aimed at patients with extensive psoriasis. Traditionally, psoriasis has been treated with drugs which, in spite of their efficacy, have a toxicity associated to their long-term use. Thus, they cannot be used safely, comfortably or efficiently in many patients. Efalizumab, a biological agent specifically and selectively directed towards blocking the key steps in the pathogenesis of psoriasis, has been shown to be effective and safe in the short and long term in the treatment of psoriasis in more than 15 phase I, II and III clinical trials. In this article, the results of efficacy at12 weeks, 6 months and three years are reviewed. Efalizumab arises as an important addition to the dermatological pharmacopoeia for the long-term treatment of psoriasis (AU)</dc:description>
<dc:creator>Galán Gutiérrez, M</dc:creator>
<dc:creator>Jiménez Puya, R</dc:creator>
<dc:creator>Moreno Giménez, JC</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Los linfocitos T juegan un papel importante en el sistema inmunológico y en la respuesta inflamatoria que determina el desarrollo y el mantenimiento de la placa de psoriasis. Un mejor entendimiento de la fisiopatología de esta enfermedad ha llevado al desarrollo de tratamientos biológicos específicos destinados apacientes con psoriasis extensa. Tradicionalmente la psoriasis ha sido tratada con fármacos que a pesar de su eficacia presentan toxicidad asociada a su utilización a largo plazo, por ello en muchos pacientes no se pueden utilizar de forma segura, cómoda o eficaz. Efalizumab, un agente biológico dirigido específica y selectivamente a bloquear pasos clave de la patogénesis de la psoriasis, ha demostrado su eficacia y seguridad a corto y largo plazo en el tratamiento de la psoriasis en más de 15 ensayos clínicos fases I, II y III. En este artículo se revisan los resultados de eficacia a 12 semanas, seis meses y tres años. Efalizumab surge como una adición importante a la farmacopea dermatológica para el tratamiento a largo plazo de la psoriasis (AU)</dc:description>
<dc:source>Actas Dermosifiliogr;99(supl.1): 9-17, ene. 2008. ilus, tab</dc:source>
<dc:identifier>ibc-62893</dc:identifier>
<dc:title xml:lang="es">Eficacia de efalizumab a corto y largo plazo</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d29623</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d29770</dc:subject>
<dc:subject>^d23473^s22031</dc:subject>
<dc:subject>^d23473^s22021</dc:subject>
<dc:subject>^d12002^s22057</dc:subject>
<dc:subject>^d3899^s22073</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d7336^s22020</dc:subject>
<dc:subject>^d920^s22079</dc:subject>
<dc:subject>^d920^s22068</dc:subject>
<dc:subject>^d920^s22078</dc:subject>
<dc:subject>^d920^s22000</dc:subject>
<dc:subject>^d24834</dc:subject>
<dc:subject>^d12225</dc:subject>
<dc:subject>^d7336^s22073</dc:subject>
<dc:subject>^d28607</dc:subject>
<dc:subject>^d920^s22073</dc:subject>
<dc:type>article</dc:type>
<dc:date>200801</dc:date>
</metadata>
</record>
</ibecs-document>
